Pfizer 2013 Annual Report Download - page 59

Download and view the complete annual report

Please find page 59 of the 2013 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 123

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123

Consolidated Statements of Equity
Pfizer Inc. and Subsidiary Companies
58
2013 Financial Report
PFIZER INC. SHAREHOLDERS
Preferred Stock Common Stock Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES) Shares
Stated
Value Shares
Par
Value
Add’l
Paid-In
Capital Shares Cost
Retained
Earnings
Accum.
Other
Comp.
Loss
Share -
holders’
Equity
Non-
controlling
Interests
Total
Equity
Balance, January 1, 2011 1,279 $ 52 8,876 $ 444 $ 70,760 (864) $(22,719) $ 42,716 $ (3,440) $ 87,813 $ 452 $ 88,265
Net income 10,009 10,009 40 10,049
Other comprehensive loss, net of tax (689) (689) (45) (734)
Cash dividends declared:
Common stock (6,512) (6,512) (6,512)
Preferred stock (3) (3) (3)
Noncontrolling interests (19) (19)
Share-based payment transactions 23 1 594 (5) (90) 505 505
Purchases of common stock (459) (9,000) (9,000) (9,000)
Preferred stock conversions and redemptions (167) (7) (2) — 1 (8) (8)
Other 3 — 71 1 4 — 75 3 78
Balance, December 31, 2011 1,112 45 8,902 445 71,423 (1,327) (31,804) 46,210 (4,129) 82,190 431 82,621
Net income 14,570 14,570 28 14,598
Other comprehensive loss, net of tax (1,824) (1,824) (7) (1,831)
Cash dividends declared:
Common stock (6,537) (6,537) (6,537)
Preferred stock (3) (3) (3)
Noncontrolling interests (9) (9)
Share-based payment transactions 52 3 1,150 (4) (97) 1,056 1,056
Purchases of common stock (349) (8,228) (8,228) (8,228)
Preferred stock conversions and redemptions (145) (6) (3) — 1 (8) (8)
Other 2 — 38 — 6 — 44 (25) 19
Balance, December 31, 2012 967 39 8,956 448 72,608 (1,680) (40,122) 54,240 (5,953) 81,260 418 81,678
Net income 22,003 22,003 69 22,072
Other comprehensive income/(loss), net of tax 2,655 2,655 (62) 2,593
Cash dividends declared:
Common stock (6,509) (6,509) (6,509)
Preferred stock (2) (2) (2)
Noncontrolling interests (121) (121)
Share-based payment transactions 95 5 2,390 (4) (99) 2,296 2,296
Purchases of common stock (563) (16,290) (16,290) (16,290)
Preferred stock conversions and redemptions (138) (6) (5) — — (11) (11)
Sale of 19.8% of subsidiary through an IPO(a) 2,297 27 2,324 155 2,479
Acquisition of common stock in exchange offer(a) (405) (11,408) (11,408) (11,408)
Deconsolidation of subsidiary sold(a) (145) (145)
Other — — (7) — (4) — (11) (1) (12)
Balance, December 31, 2013 829 $ 33 9,051 $ 453 $ 77,283 (2,652) $(67,923) $ 69,732 $ (3,271) $ 76,307 $ 313 $ 76,620
(a) Relates to Zoetis (our former Animal Health subsidiary). See Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures.
See Notes to Consolidated Financial Statements, which are an integral part of these statements.